Event/Webinar
Real World Evidence. Meet the future with confidence.
Evidence generation and dissemination in a post-COVID world.
View all IQVIA events

Thursday, June 25th, 2020

An IQVIA Virtual Conference


 

COVID-19 is impacting all of us and challenging previous ways of working. This is a period of disruption. However, we can embrace this new reality with confidence and adapt the way we work, the way we strategize, and the way we generate & disseminate real world evidence (RWE) to better inform decision making.

Stakeholders across the healthcare ecosystem (regulators, payers, providers, and patients) are adopting new solutions enabled by technology to navigate this era of change. In this new reality, RWE will take a more prominent role to improve patient outcomes, meet stakeholder needs, and answer business questions.

Join IQVIA and leading healthcare industry thought-leaders to better understand the role and importance of RWE during and after COVID-19, what it means for your business today, and how you can plan for tomorrow with confidence.


Conference Topics

We will discuss implications and provide perspectives on questions such as:

  • What new approaches, technologies, and behaviors are here to stay and what is their impact on the healthcare ecosystem? For example, how will digital technologies like telehealth impact healthcare delivery?
  • How will the pressure on site-based research and the need to reduce study-induced burden on site shift the balance between randomized clinical trials (RCTs) and RWE for regulatory submissions? How can RWD improve clinical trial efficiencies, fill evidence gaps, and accelerate approvals?
  • Which current dynamics will further accelerate the acceptance of RWE by regulators and how will payers change their decision making criteria as they operate in a more cost-constrained environment?
  • How are patients being affected by COVID-19, both in research and clinical practice? What will be the long-term impact on patients willingness to participate in research and share their health data?
  • What will be the implications to pharma and the role of RWE across the product life cycle? Will RWE generation and dissemination take a more prominent place in demonstrating value post-launch as part of commercialization efforts?
Contact Us